Diagnostic and Interventional Cardiology

CREDENCE and PACIFIC-1 study data demonstrate potential power of AI-QCT ISCHEMIA

Robust Diagnostic Accuracy and Prognostic Utility in Analyses from Large Scale Clinical Trials

March 28, 2024 — Cleerly, the company on a mission to create a new standard of care to aid in the diagnosis of heart ...

March 28, 2024

News | FDA

FDA Approves Johnson & Johnson OPSYNVI (macitentan and tadalafil) Single-Tablet Combination for Patients with Pulmonary Arterial Hypertension (PAH)

March 27, 2024 — Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has approved OPSYNVI – ...

March 27, 2024

Elixir Medical has announced it has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) for its DynamX BTK System, a novel, adaptive implant for use in the treatment of narrowed or blocked vessels below-the-knee (BTK) in patients with chronic limb-threatening ischemia (CLTI). The company reports this broadens the use of the novel bioadaptor platform technology beyond the treatment of coronary artery disease.

News | FDA

Elixir Medical Receives FDA Breakthrough Device Designation for DynamX BTK System for Below-The-Knee Arterial Disease

March 27, 2024 — Elixir Medical has announced it has been granted Breakthrough Device Designation by the U.S. Food and ...

March 27, 2024

Sponsored Content

ASCEND provides the tools that not only address the unique needs of each cardiovascular subspecialty and to care for patients from infancy into their golden years, they also innovates next-generation solutions and services that empower the provider community to truly transform their cardiovascular services

Feature | Information Technology

SPONSORED CONTENT: Unveiling the Future of Cardiovascular Workflow

Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...

March 21, 2024

The largest prospective registry of its kind will build upon clinical data supporting the use of plaque insights to empower clinical decision making for patients with suspected coronary artery disease

News | Artificial Intelligence

HeartFlow Initiates DECIDE Registry to Evaluate Utility of HeartFlow AI-Enabled Plaque Analysis for Patients with Suspected Coronary Artery Disease

March 27 2024 — HeartFlow, Inc., a leader in AI-driven healthcare technology, announced the launch of the DECIDE ...

March 27, 2024

WINREVAIR on top of background therapy significantly improved exercise capacity and multiple important secondary outcome measures compared to background therapy alone

News | FDA

FDA Approves Merck’s WINREVAIR, a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension

March 27, 2024 — Merck, known as MSD outside of the United States and Canada, announced that the U.S. Food and Drug ...

March 27, 2024

Esperion announced the acceptance of three CLEAR (Cholesterol Lowering via Bempedoic acid, an ACL-Inhibiting Regimen) Outcomes subgroup analyses as poster presentations at ACC24

News | Cardiovascular Clinical Studies

Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session and Industry Expert Theatre to be Presented at ACC.24

March 26, 2024 — Esperion announced the acceptance of three CLEAR (Cholesterol Lowering via Bempedoic acid, an ACL ...

March 26, 2024

Sponsored Content

Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability to diagnose cardiac disease with greater accuracy and precision

Feature | Cardiac Imaging

SPONSORED CONTENT: Finding the Right Solution

Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...

March 05, 2024

Medical imaging AI company receives approval for algorithms enabling incidental detection of pulmonary embolism and automatic assessment of stroke severity

News | FDA

Avicenna.AI Secures FDA Clearance for Two Healthcare AI Solutions

March 26, 2024 — Medical imaging AI company Avicenna.AI announced that it has received 510(k) clearance from the US Food ...

March 26, 2024

Bristol Myers Squibb has announced that it will present data on CAMZYOS (mavacamten) for NYHA class II-III obstructive hypertrophic cardiomyopathy at the American College of Cardiology (ACC) Annual Scientific Session & Expo, ACC.24, taking place April 6-8, 2024 in Atlanta, Georgia.

News | ACC

Bristol Myers Squibb to Present Data on CAMZYOS (mavacamten) for obstructive hypertrophic cardiomyopathy (HCM) at American College of Cardiology Annual Scientific Session, ACC.24

March 26, 2024 — Bristol Myers Squibb has announced that it will present data on CAMZYOS (mavacamten) for NYHA class II ...

March 26, 2024

UC San Diego Health is the first in San Diego to successfully implant the world’s first dual chamber and leadless pacemaker system to help treat people with abnormal heart rhythms

News | Pacemakers

UC San Diego Health First in Region to Implant Dual Chamber, Leadless Pacemaker

March 26, 2024 — UC San Diego Health is the first health system in San Diego to successfully implant the world’s first ...

March 26, 2024

Sponsored Content

Blog

BLOG: Combining Local Impedance with Contact Force to Perform RF Ablation

When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...

December 11, 2023

Here is a look at the education and special events planned for the ACC24 73rd Annual Scientific Session & Expo, April 6-8 in Atlanta

Feature | ACC | By Melinda Taschetta-Millane

American College of Cardiology (ACC24) Show Preview: Advancing Cardiovascular Care for All

The American College of Cardiology (ACC) has announced key educational and programming highlights for its ACC 73rd ...

March 25, 2024

The cutting-edge procedure that avoids open-heart surgery is momentous in cardiac care

News | Structural Heart

CLS Health Cardiologists Achieve Historic First with Transcarotid TAVR in Southeast Houston

March 25, 2024 — In a groundbreaking medical advancement, three esteemed cardiologists from CLS Health, Dr. Bahaeddin ...

March 25, 2024

Abbott announced the first patient has been enrolled in the ENVISION investigational device exemption (IDE) clinical trial.

News | Cardiovascular Clinical Studies

Abbott Announces First Procedures in ENVISION Trial of Navitor TAVI System to Treat Patients With Severe Aortic Stenosis

March 25, 2024 — Abbott announced the first patient has been enrolled in the ENVISION investigational device exemption ...

March 25, 2024

Sponsored Content

Case Study | Hemodynamic Monitoring Systems

TECH BRIEF — Integrated Hemodynamic Monitoring System Helps Improve Lab Performance, Efficiency

Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...

November 14, 2023

A bioelectronic mesh, studded with graphene sensors (red), can measure the electrical signal and movement of cardiac tissue (purple and green) at the same time.

News | Heart Failure

UMass Amherst Engineers Create Bioelectronic Mesh Capable of Growing with Cardiac Tissues for Comprehensive Heart Monitoring

March 25, 2024 — A team of engineers led by the University of Massachusetts Amherst and including colleagues from the ...

March 25, 2024

The U.S. Food and Drug Administration (FDA) announced that Abiomed is recalling the Instructions for Use for its Impella Left Sided Blood Pumps because the pump catheter may perforate (cut) the wall of the left ventricle in the heart.

News | FDA

FDA Announces Abiomed Recall of the Instructions for Use for the Impella Left Sided Blood Pumps due to Perforation Risks

March 21, 2024 — The U.S. Food and Drug Administration (FDA) announced that Abiomed is recalling the Instructions for ...

March 21, 2024

Association Between Prognostic Implications of Platelet FCɣRIIA (PFCG) and Treatment Strategy for Myocardial Infarction

News | ACC

Prolocor to Present New Clinical Evidence at ACC 24 Supporting the Use of PLATELET FCɣRIIA (PFCG) as a Key Tool in Individualizing Dual Antiplatelet Therapy (DAPT)

March 21, 2024 — Prolocor, Inc., a healthcare startup developing an innovative precision diagnostic test with the goal ...

March 21, 2024